Target type: biologicalprocess
Covalent attachment of a glycosyl residue to a lipid molecule. [GOC:mah]
Lipid glycosylation is a crucial process in cellular biology, involving the covalent attachment of glycans (sugar chains) to lipid molecules. This process plays a vital role in diverse cellular functions, including cell signaling, recognition, adhesion, and membrane integrity. Here's a detailed explanation:
1. **Glycosyltransferases and Lipid Substrates:** The process begins with the action of glycosyltransferases, a family of enzymes responsible for transferring sugar moieties from donor molecules (often nucleotide sugars like UDP-glucose or GDP-mannose) to specific lipid acceptors. The most common lipid substrates include ceramide (forming glycosphingolipids), diacylglycerol (forming glycoglycerolipids), and phosphatidylinositol (forming glycophosphatidylinositols).
2. **Glycan Structures and Diversity:** The glycans attached to lipids can exhibit remarkable structural diversity, ranging from simple monosaccharides to complex branched oligosaccharides. This diversity arises from the various glycosyltransferases and their specificities, as well as the sequential addition of different sugar residues.
3. **Biosynthetic Pathways:** Lipid glycosylation follows distinct pathways depending on the specific lipid and glycan involved. For instance, glycosphingolipid biosynthesis occurs in the Golgi apparatus, where ceramide is sequentially glycosylated to form complex glycosphingolipids like gangliosides. Glycoglycerolipids, on the other hand, are synthesized in the endoplasmic reticulum and often play roles in plant membranes.
4. **Functions in Cellular Processes:**
* **Cell Signaling:** Lipid glycosylation is essential for the formation of cell surface receptors and ligands involved in cell signaling pathways. For example, glycosphingolipids serve as anchors for growth factor receptors, while glycophosphatidylinositols (GPIs) attach proteins to the plasma membrane, facilitating signal transduction.
* **Cell Recognition and Adhesion:** Glycans on lipids are crucial for cell-cell and cell-matrix interactions. They mediate recognition events between cells, contribute to tissue development, and play roles in immune responses.
* **Membrane Integrity and Stability:** Lipid glycosylation contributes to the structural integrity and stability of cellular membranes. Glycans on lipids can influence membrane fluidity, permeability, and protein interactions, ensuring proper membrane function.
* **Protection and Detoxification:** Glycolipids in certain organisms, like plants, provide protection against environmental stressors and pathogens. They also play roles in detoxification processes, eliminating harmful substances from the cell.
5. **Regulation and Control:** Lipid glycosylation is tightly regulated by various factors, including the expression levels of glycosyltransferases, availability of donor sugars, and cellular location. This ensures precise control over the synthesis and modification of glycolipids, ensuring proper cellular function.
6. **Disease Implications:** Defects in lipid glycosylation pathways can lead to various diseases. Genetic disorders affecting glycosyltransferases or lipid metabolism can result in developmental abnormalities, metabolic diseases, and neurological disorders. Disruptions in lipid glycosylation can also contribute to cancer progression and inflammation.
Overall, lipid glycosylation is a complex and crucial process that plays a diverse array of roles in cellular biology. Its importance extends beyond membrane structure and encompasses various cellular functions, highlighting the intricate interplay between lipids and glycans in maintaining cell homeostasis and function.'
"
Protein | Definition | Taxonomy |
---|---|---|
Lysosomal acid glucosylceramidase | A lysosomal acid glucosylceramidase that is encoded in the genome of cow. [OMA:Q2KHZ8, PRO:DNx] | Bos taurus (cattle) |
Non-lysosomal glucosylceramidase | A non-lysosomal glucosylceramidase that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9HCG7] | Homo sapiens (human) |
Lysosomal acid glucosylceramidase | A lysosomal acid glucosylceramidase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P04062] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
ambroxol | Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride. | aromatic amine | |
beta-glucono-1,5-lactone | beta-glucono-1,5-lactone: structure D-glucono-1,5-lactone : An aldono-1,5-lactone obtained from D-gluconic acid. | aldono-1,5-lactone; gluconolactone | animal metabolite; mouse metabolite |
1-deoxynojirimycin | 1-deoxy-nojirimycin: structure in first source duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration. | 2-(hydroxymethyl)piperidine-3,4,5-triol; piperidine alkaloid | anti-HIV agent; anti-obesity agent; bacterial metabolite; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; plant metabolite |
miglustat | miglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group. miglustat: a glucosylceramide synthase inhibitor | piperidines; tertiary amino compound | anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor |
castanospermine | castanospermine : A tetrahydroxyindolizidine alkaloid that consists of octahydroindolizine having four hydroxy substituents located at positions 1, 6, 7 and 8 (the 1S,6S,7R,8R,8aR-diastereomer). castanospermine: indolizidine alkaloid from seeds of Australian legume, Castanospermum australe | indolizidine alkaloid | anti-HIV-1 agent; anti-inflammatory agent; EC 3.2.1.* (glycosidase) inhibitor; metabolite |
n-phenylphthalimide | N-phenylphthalimide: structure given in first source | ||
fagomine | fagomine: structure in first source | piperidines | |
N-Benzylphthalimide | isoindoles | ||
1-(10h-phenothiazin-2-yl)ethanone | 1-(10H-phenothiazin-2-yl)ethanone: structure in first source | phenothiazines | |
mor-14 | N-methyldeoxynojirimycin: glucosidase inhibitor | hydroxypiperidine; piperidine alkaloid; tertiary amino compound | anti-HIV agent; cardioprotective agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; plant metabolite |
1,2,3,4-tetrahydroxy-nor-tropane | calystegine B(2): RN given for (2-endo,3-exo,4-endo)-isomer; structure in first source | ||
2,5-dihydroxymethyl-3,4-dihydroxypyrrolidine | 2,5-dihydroxymethyl-3,4-dihydroxypyrrolidine: structure given in first source | dihydroxypyrrolidine | |
homonojirimycin | homonojirimycin: inhibits alpha-glucosidase; RN given for (2R-(2alpha,3alpha,4beta,5alpha,6beta))-isomer; structure in first source | ||
cyclophellitol | cyclophellitol: structure given in first source; isolated from Phellinus sp. | ||
migalastat | migalastat: a potent inhibitor of glycolipid biosynthesis | piperidines | |
calystegine a3 | calystegine A3: also inhibits beta-xylosidase; structure in first source | ||
miglitol | piperidines | ||
isofagomine | piperidines | ||
1,4-dideoxy-1,4-imino-d-arabinitol | |||
n-nonyl-1-deoxynojirimycin | N-nonyldeoxynojirimycin : A hydroxypiperidine that is deoxynojirimycin (duvoglustat) in which the amino hydrogen is replaced by a nonyl group. | hydroxypiperidine; tertiary amino compound | antiviral agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; EC 3.2.1.45 (glucosylceramidase) inhibitor |
1-(1-benzimidazolyl)-3-(1-cyclohex-3-enylmethoxy)-2-propanol | benzimidazoles | ||
2-(2-phenylethylthio)-3-pyridinecarboxylic acid | aromatic carboxylic acid; pyridines | ||
4-(2-furanylmethyl)-3-(phenylmethyl)-1H-1,2,4-triazole-5-thione | benzenes | ||
2-[[4-(4-chloroanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | dialkylarylamine; tertiary amino compound | ||
4-(benzenesulfonamido)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)benzamide | sulfonamide | ||
tamoxifen | stilbenoid; tertiary amino compound | angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator | |
4-oxido-3-(4-phenoxyphenyl)-4a,5,6,7,8,8a-hexahydroquinoxalin-1-ium 1-oxide | aromatic ether | ||
2-[[4-(3-methylanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | dialkylarylamine; tertiary amino compound | ||
N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amine | N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amine : A member of the class of quinazolines that is quinazoline which is substituted by a pyridin-3-yl group and a (1-benzylpiperidin-4-yl)nitrilo group at positions 2 and 4, respectively. | aromatic amine; piperidines; pyridines; quinazolines; secondary amino compound; tertiary amino compound | |
N-[4-methyl-2-(4-morpholinyl)-6-quinolinyl]cyclohexanecarboxamide | aminoquinoline | ||
n-(5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin | |||
ogt2378 | sinbaglustat: an antineopl agent; structure in first source | ||
nnc 26-9100 | NNC 26-9100: structure in first source | aminopyridine | |
3-epi-fagomine | 3-epi-fagomine : A member of the class of hydroxypiperidines that is piperidine carrying a hydroxymethyl substituent at position 2 as well as two hydroxy substituents at positions 3 and 4 (the 2R,3R,4S-diastereomer). | amino monosaccharide; hydroxypiperidine; primary alcohol; secondary alcohol; secondary amino compound; triol | EC 3.2.1.10 (oligo-1,6-glucosidase) inhibitor; EC 3.2.1.23 (beta-galactosidase) inhibitor; plant metabolite |
l-altro-1-deoxynojirimycin | L-altro-1-deoxynojirimycin: structure in first source | ||
2-[[4-[2-[(2-methylpropan-2-yl)oxy]anilino]-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | aromatic ether | ||
2-[[4-(5-chloro-2-methoxyanilino)-6-(1-piperidinyl)-1,3,5-triazin-2-yl]amino]ethanol | methoxybenzenes; substituted aniline | ||
2-[[4-(4-methylanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | dialkylarylamine; tertiary amino compound | ||
2-[[4-(2-chloroanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | dialkylarylamine; tertiary amino compound | ||
2-[[4-(2-methoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | methoxybenzenes; substituted aniline | ||
2-[[4-(3-methoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | methoxybenzenes; substituted aniline | ||
2-[[4-(4-methoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | methoxybenzenes; substituted aniline | ||
2-[[4-(2-hydroxyethylamino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]phenol | dialkylarylamine; tertiary amino compound | ||
2-[[4-(2-phenoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | aromatic ether | ||
2-[[4-(1-pyrrolidinyl)-6-[2-(trifluoromethoxy)anilino]-1,3,5-triazin-2-yl]amino]ethanol | aromatic ether | ||
2-[[4-(5-chloro-2-ethoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | aromatic ether | ||
2-[[4-(5-chloro-2-propan-2-yloxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | aromatic ether |